Baylor Miraca Announces Strategic Partnership with Diversigen
News Feb 26, 2016
Baylor Miraca has announced a strategic partnership with Diversigen, Inc. to provide its customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
“Partnering with Diversigen gives us a tremendous opportunity to extend our reach into new markets, while maintaining a very clear and aligned path towards improving patient health around personalized medicine,” said Gary Huff, Baylor Miraca President and CEO.
According to Cynthia Sheridan, Diversigen President, “Our pharmaceutical customers have expressed an interest in correlating microbiome data with specific host genetic traits to better understand the host-microbiome relationship as a factor in disease and in the search for more effective therapies. This partnership with BMGL will allow us to provide broader services resulting in deeper insights into human health and disease.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.